Alnylam and Tenaya Therapeutics sign deal to discover cardiovascular targets totaling $1.23 billion. The agreement focuses on the development of new therapies in the field of cardiovascular diseases. Alnylam enters into this collaboration to replicate the success of its marketed ATTR-CM therapy called Amvuttra. Amvuttra is a successful treatment for cardiac amyloidosis (ATTR-CM). The companies plan joint research to identify new drug targets. The deal includes potential milestone payments and shares of sales.